{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:12:41Z","timestamp":1760242361607},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,12,11]],"date-time":"2007-12-11T00:00:00Z","timestamp":1197331200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1245\/s10434-007-9712-1","type":"journal-article","created":{"date-parts":[[2007,12,10]],"date-time":"2007-12-10T22:30:58Z","timestamp":1197325858000},"page":"484-492","source":"Crossref","is-referenced-by-count":5,"title":["Fluorescence in situ Hybridization and Immunohistochemical Analysis of p53 Expression in Endometrial Cancer: Prognostic Value and Relation to Ploidy"],"prefix":"10.1245","volume":"15","author":[{"given":"Olivier","family":"Graesslin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Chantot-Bastaraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Lorenzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Birembaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Qu\u00e9reux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emile","family":"Dara\u00ef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,12,11]]},"reference":[{"key":"9712_CR1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.ede.0000221026.49643.cf","volume":"17","author":"LS Cook","year":"2006","unstructured":"Cook LS, Kmet LM, Magliocco AM, et al. Endometrial cancer survival among U.S. black and white women by birth cohort. Epidemiology 2006; 17:469\u201372","journal-title":"Epidemiology"},{"key":"9712_CR2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJM199608293350907","volume":"335","author":"PG Rose","year":"1996","unstructured":"Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335:640\u20139","journal-title":"N Engl J Med"},{"key":"9712_CR3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","volume":"86","author":"B Fisher","year":"1994","unstructured":"Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527\u201337","journal-title":"J Natl Cancer Inst"},{"key":"9712_CR4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/(SICI)1097-0215(19980504)76:3<325::AID-IJC7>3.0.CO;2-X","volume":"76","author":"H Mignotte","year":"1998","unstructured":"Mignotte H, Lasset C, Bonadona V, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. FNCLCC. Int J Cancer 1998; 76:325\u201330","journal-title":"Int J Cancer"},{"key":"9712_CR5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/0002-9343(94)90091-4","volume":"96","author":"P Watson","year":"1994","unstructured":"Watson P, Vasen HF, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96:516\u201320","journal-title":"Am J Med"},{"key":"9712_CR6","doi-asserted-by":"crossref","first-page":"7621","DOI":"10.1038\/sj.onc.1203285","volume":"18","author":"P May","year":"1999","unstructured":"May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 1999; 18:7621\u201336","journal-title":"Oncogene"},{"key":"9712_CR7","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.onc.1204101","volume":"20","author":"P Drane","year":"2001","unstructured":"Drane P, Bravard A, Bouvard V, et al. Reciprocal downregulation of p53 and SOD2 gene expression: implication in p53 mediated apoptosis. Oncogene 2001; 20:430\u20139","journal-title":"Oncogene"},{"key":"9712_CR8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cdp.2003.09.005","volume":"27","author":"A Mariani","year":"2003","unstructured":"Mariani A, Sebo TJ, Webb MJ, et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prevent 2003; 27:434\u201341","journal-title":"Cancer Detect Prevent"},{"key":"9712_CR9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004347-200404000-00007","volume":"23","author":"A Alkushi","year":"2004","unstructured":"Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynaecol Pathol 2004; 23:129\u201337","journal-title":"Int J Gynaecol Pathol"},{"key":"9712_CR10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0301-2115(00)00562-5","volume":"98","author":"PJ Coronado","year":"2001","unstructured":"Coronado PJ, Vidart JA, Lopez-Asenjo JA. P53 overexpression predicts endometrial carcinoma better than HER-2\/neu overexpression. Eur J Obstet Gynecol Reprod Biol 2001; 98:103\u20138","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"9712_CR11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejogrb.2005.03.018","volume":"123","author":"N Ragni","year":"2005","unstructured":"Ragni N, Ferrero S, Prefumo F, et al. The association between p53 expression, stage and histological features in endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2005; 123:111\u20136","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"9712_CR12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/modpathol.3880062","volume":"13","author":"S Kounelis","year":"2000","unstructured":"Kounelis S, Kapranos N, Kouri E, et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000; 13:379\u201388","journal-title":"Mod Pathol"},{"key":"9712_CR13","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1073\/pnas.88.11.5006","volume":"88","author":"AM Davidoff","year":"1991","unstructured":"Davidoff AM, Humphrey PA, Iglehart JD, et al. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991; 88:5006\u201310","journal-title":"Proc Natl Acad Sci USA"},{"key":"9712_CR14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0140-6736(90)90801-B","volume":"335","author":"R Iggo","year":"1990","unstructured":"Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335:675\u20139","journal-title":"Lancet"},{"key":"9712_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.1711720103","volume":"172","author":"PA Hall","year":"1994","unstructured":"Hall PA, Lane DP. P53 in tumour pathology: can we trust immunohistochemistry? J Pathol 1994; 172:1\u20134","journal-title":"J Pathol"},{"key":"9712_CR16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/bjc.1996.401","volume":"74","author":"R Soong","year":"1996","unstructured":"Soong R, Knowles S, Williams KE, et al. Overp53 expression protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 1996; 74:562\u20137","journal-title":"Br J Cancer"},{"key":"9712_CR17","first-page":"728","volume":"10","author":"M Taskin","year":"1997","unstructured":"Taskin M, Lallas TA, Barber HR, et al. bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 1997; 10:728\u201334","journal-title":"Mod Pathol"},{"key":"9712_CR18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.PGP.0000070850.25718.A5","volume":"22","author":"O Erdem","year":"2003","unstructured":"Erdem O, Erdem M, Dursun A, et al. Angiogenesis, p53, and bcl-2 expression as prognostic factors in endometrial cancer: comparison with traditional clinicopathological variables. Int J Gynecol Pathol 2003; 22:254\u201360","journal-title":"Int J Gynecol Pathol"},{"key":"9712_CR19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1006\/gyno.1996.0120","volume":"61","author":"W Zheng","year":"1996","unstructured":"Zheng W, Cao P, Zheng M, et al. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996; 61:167\u201374","journal-title":"Gynecol Oncol"},{"key":"9712_CR20","first-page":"4667","volume":"54","author":"K Ito","year":"1994","unstructured":"Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994; 54:4667\u201370","journal-title":"Cancer Res"},{"key":"9712_CR21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/exmp.1999.2289","volume":"67","author":"JA Williams Jr","year":"1999","unstructured":"Williams JA Jr, Wang ZR, Parrish RS, et al. Fluorescence in situ hybridization analysis of Her-2\/neu, c-myc and p53 in endometrial cancer. Exp Mol Pathol 1999; 67:135\u201343","journal-title":"Exp Mol Pathol"},{"key":"9712_CR22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3322\/canjclin.44.3.136","volume":"44","author":"AA Sandberg","year":"1994","unstructured":"Sandberg AA. Cancer cytogenetics for clinicians. Ca Cancer J Clin 1994; 44:136\u201359","journal-title":"Ca Cancer J Clin"},{"key":"9712_CR23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/gyno.1999.5365","volume":"73","author":"P Lim","year":"1999","unstructured":"Lim P, Aquino-Parsons CF, Wong F, et al. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators. Gynecol Oncol 1999; 73:191\u20135","journal-title":"Gynecol Oncol"},{"key":"9712_CR24","first-page":"5191","volume":"23","author":"M Santala","year":"2003","unstructured":"Santala M, Talvensaari-Mattila A. DNA ploidy is an independent prognostic indicator of overall survival in stage I endometrial endometrioid carcinoma. Anticancer Res 2003; 23:5191\u201396","journal-title":"Anticancer Res"},{"key":"9712_CR25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","volume":"70","author":"JL Benedet","year":"2000","unstructured":"Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynaecologic cancers. FIGO committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70:209\u201362","journal-title":"Int J Gynaecol Obstet"},{"key":"9712_CR26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000133333","volume":"60","author":"A Kallioniemi","year":"1992","unstructured":"Kallioniemi A, Kallioniemi OP, Waldman FM, et al. Detection of retinoblastoma gene copy number in metaphase chromosomes and interphase nuclei by fluorescence in situ hybridization. Cytogenet Cell Genet 1992; 60:190\u20133","journal-title":"Cytogenet Cell Genet"},{"key":"9712_CR27","first-page":"922","volume":"73","author":"JS Jong De","year":"1995","unstructured":"De Jong JS, Van Diest PJ, Baak JPA. Methods in laboratory investigation. Heterogeneity and reproducibility of microvessel counts in breast cancer. Lab Invest 1995; 73:922\u20136","journal-title":"Lab Invest"},{"key":"9712_CR28","first-page":"9","volume":"147","author":"N Weidner","year":"1995","unstructured":"Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147:9\u201319","journal-title":"Am J Pathol"},{"key":"9712_CR29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1053\/hupa.2001.25929","volume":"32","author":"X Matias-Guiu","year":"2001","unstructured":"Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32:569\u201377","journal-title":"Hum Pathol"},{"key":"9712_CR30","first-page":"177","volume":"150","author":"H Tashiro","year":"1997","unstructured":"Tashiro H, Isacson C, Levine R, et al. P53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150:177\u201385","journal-title":"Am J Pathol"},{"key":"9712_CR31","first-page":"1917","volume":"56","author":"AS Jovanovic","year":"1996","unstructured":"Jovanovic AS, Boynton KA, Mutter GL. Uteri of women with endometrial carcinoma contain a histopathologic spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res 1996; 56:1917\u201321","journal-title":"Cancer Res"},{"key":"9712_CR32","first-page":"27","volume":"9","author":"MK Oehler","year":"2003","unstructured":"Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc 2003; 9:27\u201331","journal-title":"J Br Menopause Soc"},{"key":"9712_CR33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ijc.2910580104","volume":"58","author":"M Inoue","year":"1994","unstructured":"Inoue M, Okayama A, Fujita M, et al. Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer 1994; 58:14\u20139","journal-title":"Int J Cancer"},{"key":"9712_CR34","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/1097-0142(19940501)73:9<2380::AID-CNCR2820730922>3.0.CO;2-G","volume":"73","author":"AS Lukes","year":"1994","unstructured":"Lukes AS, Kohler MF, Pieper CF, et al. Multivariable analysis of DNA ploidy, P53, and HER-2\/NEU as prognostic factors in endometrial cancer. Cancer 1994; 73:2380\u20135","journal-title":"Cancer"},{"key":"9712_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00129039-200403000-00001","volume":"12","author":"AS-Y Leong","year":"2004","unstructured":"Leong AS-Y. Quantitation in immunohistology: fact or fiction? Appl Immunohistochem Mol Morphol 2004; 12:1\u20137","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"9712_CR36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.pgp.0000167113.86586.65","volume":"24","author":"WG McCluggage","year":"2005","unstructured":"McCluggage WG, Connolly LE, McGregor G, et al. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int J Gynecol Pathol 2005; 24:307\u201312","journal-title":"Int J Gynecol Pathol"},{"key":"9712_CR37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/path.1838","volume":"207","author":"R Nenutil","year":"2005","unstructured":"Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005; 207:251\u20139","journal-title":"J Pathol"},{"key":"9712_CR38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/path.1711660402","volume":"166","author":"D Wynford-Thomas","year":"1992","unstructured":"Wynford-Thomas D. P53 in tumour pathology: can we trust immunohistochemistry? J Pathol 1992; 166:329\u201330","journal-title":"J Pathol"},{"key":"9712_CR39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35106009","volume":"1","author":"T Soussi","year":"2001","unstructured":"Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Rev Cancer 2001; 1:233\u201340","journal-title":"Nature Rev Cancer"},{"key":"9712_CR40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/humu.20114","volume":"25","author":"T Soussi","year":"2005","unstructured":"Soussi T, Kato S, Levy PP, et al. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 2005; 25:6\u201317","journal-title":"Hum Mutat"},{"key":"9712_CR41","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1128\/MCB.16.9.4952","volume":"16","author":"RL Ludwig","year":"1996","unstructured":"Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996; 16:4952\u201360","journal-title":"Mol Cell Biol"},{"key":"9712_CR42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000089764","volume":"69","author":"A Semczuk","year":"2005","unstructured":"Semczuk A, Marzec B, Skomra D, et al. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas. Oncology 2005; 69:317\u201325","journal-title":"Oncology"},{"key":"9712_CR43","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1046\/j.1365-2559.1998.00499.x","volume":"33","author":"RL Stewart","year":"1998","unstructured":"Stewart RL, Royds JA, Burton JL, et al. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology 1998; 33:440\u20135","journal-title":"Histopathology"},{"key":"9712_CR44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/gyno.1993.1157","volume":"50","author":"RL Coleman","year":"1993","unstructured":"Coleman RL, Schinck JC, Miller DS, et al. DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases. Gynecol Oncol 1993; 50:20\u20134","journal-title":"Gynecol Oncol"},{"key":"9712_CR45","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2004.08.031","volume":"95","author":"K Terada","year":"2004","unstructured":"Terada K, Mattson D, Goo D, et al. DNA aneuploidy is associated with increased mortality for stage I endometrial cancer. Gynecol Oncol 2004; 95:483\u20137","journal-title":"Gynecol Oncol"},{"key":"9712_CR46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/02841860310018990","volume":"43","author":"C Lundgren","year":"2000","unstructured":"Lundgren C, Auer G, Frankendal B, et al. Prognostic factors in surgical stage I endometrial carcinoma. Acta Oncol 2000; 43:49\u201356","journal-title":"Acta Oncol"},{"key":"9712_CR47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1525-1438.2002.01074.x","volume":"12","author":"A Orbo","year":"2002","unstructured":"Orbo A, Rydningen M, Straume B, et al. Significance of morphometric, DNA cytometric features, and other prognostic markers on survival of endometrial cancer patients in Northern Norway. Int J Gynecol Cancer 2002; 12:49\u201356","journal-title":"Int J Gynecol Cancer"},{"key":"9712_CR48","first-page":"123","volume":"23","author":"S Biesterfeld","year":"2001","unstructured":"Biesterfeld S, Leitloff M, Rath W, et al. DNA image cytometry in the differential diagnosis of endometrial hyperplasia and adenocarcinoma. Analyt Quant Cytol Histol 2001; 23:123\u20138","journal-title":"Analyt Quant Cytol Histol"},{"key":"9712_CR49","first-page":"64","volume":"26","author":"MA Osmanagaoglu","year":"2005","unstructured":"Osmanagaoglu MA, Kadioglu S, Osmanagaoglu S, et al. The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma. Eur J Gynaecol Oncol 2005; 26:64\u201370","journal-title":"Eur J Gynaecol Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-007-9712-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-007-9712-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-007-9712-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T16:27:55Z","timestamp":1572971275000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-007-9712-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,11]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["9712"],"URL":"https:\/\/doi.org\/10.1245\/s10434-007-9712-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,11]]}}}